Non-regulatory Press releases
KOMMUNIKÉ FRÅN ÅRSSTÄMMA I PILA PHARMA AB 2025
Malmö, 29 April 2025 PILA PHARMA AB (publ) höll på torsdagen den 29 april 2025 årsstämma hos MAQS Advokatbyrå, Gibraltargatan 7 i Malmö. Följande huvudsakliga beslut fattades:Fastställande av resultat- och balansräkningarÅrsstämman fastställde bolagets resultat- och balansräkning för räkenskapsåret 2024. ResultatdispositionÅrsstämman beslutade att ingen utdelning ska lämnas för räkenskapsåret 2024. Beslut om ansvarsfrihetÅrsstämman beviljade styrelsen och verkställande direktören ansvarsfrihet för förvaltningen…
PILA PHARMA UPCOMING INVESTOR MEETINGS
Malmö, 25 April 2025 PILA PHARMA AB (publ) (FN STO: PILA) hereby invites investors and others with interest in the Company, to meet PILA PHARMA at these upcoming events: Malmömorgon (Slagthuset, Malmö, Sweden)Monday 28 April 2025 from 07:00 CESTFounder & CSO Dorte X. Gram will participate in a panel debate on creativity, entrepreneurial spirit and the courage to think 'out…
PILA PHARMA: REMINDER – LAST DAY FOR SHAREHOLDER REGISTRATION FOR ANNUAL GENERAL MEETING
Malmö, 23 April 2025 PILA PHARMA AB (publ) (FN STO: PILA) today reminds shareholders that today, 23 April is the last day to register attendance at this year's Annual General meeting. PILA PHARMA welcomes all shareholders to attend and exercise their vote, either by actual attendance or via proxy! The meeting will be held on Tuesday, 29 April 2025 at…
PILA PHARMA INVITES TO H2 REPORT WEBINAR & INVESTOR Q&A
Malmö, February 24, 2025 PILA PHARMA AB (publ) (FN STO: PILA) hereby invites interested investors to participate in our scheduled H2 Report event in the coming week: ___________Stokk.io Online Webinar - H2 Report (ONLINE)Thursday, February 27, 2025 from 15:00 CET __________CEO Gustav H. Gram will elaborate on the company's second half-year report for 2024 and answer questions about PILA PHARMA and…
PILA PHARMA ANNOUNCES INITIATION OF STUDY IN PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE
Malmö, 21 November 2024 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the initiation of the study associated to the co-sponsorship of the research collaboration with the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden (the "Research Group"). The aim is to complete initial investigations on the effect of PILA PHARMA's lead molecule, XEN-D0501, on Abdominal Aorta…